S
Stanley R. Pillemer
Researcher at National Institutes of Health
Publications - 82
Citations - 7969
Stanley R. Pillemer is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Population & Rheumatoid arthritis. The author has an hindex of 34, co-authored 82 publications receiving 7708 citations. Previous affiliations of Stanley R. Pillemer include University of Toronto & University of Chicago.
Papers
More filters
Journal ArticleDOI
Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States
Reva C. Lawrence,Charles G. Helmick,Frank C. Arnett,Richard A. Deyo,David T. Felson,Edward H. Giannini,Stephen P. Heyse,Rosemarie Hirsch,Marc C. Hochberg,Gene G. Hunder,Matthew H. Liang,Stanley R. Pillemer,Virginia D. Steen,Frederick Wolfe +13 more
TL;DR: Given the limitations of the data on which they are based, this report provides the best available prevalence estimates for arthritis and other rheumatic conditions overall, and for selected musculoskeletal disorders, in the US population.
Journal ArticleDOI
Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia.
Leslie J. Crofford,Stanley R. Pillemer,Konstantine T. Kalogeras,Joseph M. Cash,David Michelson,Mitchel A. Kling,Esther M. Sternberg,Philip W. Gold,George P. Chrousos,Ronald L. Wilder +9 more
TL;DR: The view that HPA axis function is perturbed in patients with FM is supported, with a significant decrease in net integrated cortisol response to oCRH in FM patients, indicating adrenal hyporesponsiveness.
Journal ArticleDOI
Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial.
Nicole A. Sherry,William Hagopian,Johnny Ludvigsson,Sunil M Jain,Jack Wahlen,Robert J. Ferry,Bruce W. Bode,S. Aronoff,Christopher Holland,David Carlin,Karen L King,Ronald L. Wilder,Stanley R. Pillemer,Ezio Bonvini,Syd Johnson,Kathryn E. Stein,Scott Koenig,Kevan C. Herold,Anastasia G. Daifotis +18 more
TL;DR: It is suggested that future studies of immunotherapeutic intervention with teplizumab might have increased success in prevention of a decline in β-cell function (measured by C-peptide) and provision of glycaemic control at reduced doses of insulin if they target patients early after diagnosis of diabetes and children.
Journal ArticleDOI
Xerostomia and the geriatric patient
TL;DR: Treatments for salivary problems are based upon establishing a diagnosis, protecting oral and pharyngeal health, stimulating remaining glands, and replacing lostSalivary fluids.
Journal ArticleDOI
Minocycline in rheumatoid arthritis : a 48-week, double-blind, placebo-controlled trial
Barbara C. Tilley,Graciela S. Alarcón,Stephen P. Heyse,David E. Trentham,Rosemarie Neuner,David L. Kaplan,Daniel O. Clegg,James C. C. Leisen,Lenore M. Buckley,Sheldon M. Cooper,Howard Duncan,Stanley R. Pillemer,Marilyn Tuttleman,Sarah Fowler +13 more
TL;DR: A 48-week, randomized, double-blind, multicenter trial to determine the efficacy and safety of minocycline in treating rheumatoid arthritis when it is added to background NSAIDs or low-dose prednisone therapy in patients not receiving concomitant disease-modifying antirheumatic drugs.